Pregled bibliografske jedinice broj: 85548
Adult respiratory tract Infections: Single Dose Azithromycin vs. 3-day Azithromycin vs. Clarithromycin in the Treatment of Atypical Community-Acquired Pneumoniae in Adultszithromycin, community acquired
Adult respiratory tract Infections: Single Dose Azithromycin vs. 3-day Azithromycin vs. Clarithromycin in the Treatment of Atypical Community-Acquired Pneumoniae in Adultszithromycin, community acquired // The Sixth International Conference on the Macrolides, Azalides, Streptogramins, Ketolides and Oxazolidinones - ICMASKO6 - Program & Abstracts
Bologna, Italija, 2002. (poster, nije recenziran, sažetak, ostalo)
CROSBI ID: 85548 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Adult respiratory tract Infections: Single Dose Azithromycin vs. 3-day Azithromycin vs. Clarithromycin in the Treatment of Atypical Community-Acquired Pneumoniae in Adultszithromycin, community acquired
(Adult respiratory tract Infections: Single Dose Azithromycin vs. 3-day Azithromycin vs. Clarithromycin in the Treatment of Atypical Community-Acquired Pneumoniae in Adults)
Autori
Schonwald, Slavko ; Kuzman, Ilija ; Škerk, Višnja ; Car, Vladimir ; Zrinšćak, Jagoda ; Mahovlić, Vjekoslav ; Puljiz, Ivan ; Leskovar, Vladimira ; Mutvar, A. ; Welle-Jeras, A. ; Banaszak, Andrej
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, ostalo
Skup
The Sixth International Conference on the Macrolides, Azalides, Streptogramins, Ketolides and Oxazolidinones - ICMASKO6 - Program & Abstracts
Mjesto i datum
Bologna, Italija, 23.01.2002. - 25.01.2002
Vrsta sudjelovanja
Poster
Vrsta recenzije
Nije recenziran
Ključne riječi
respiratory tract infections; azithromycin; community acquired penumonia
Sažetak
The aim of this open, comparative, randomized study was to compare the efficacy and safety of a single 1.5 g dose of azithromycin with standard 3-day azithromycin regimen and with 10-day course of clarithromycin in the treatment of communitiy-acquired pneumonia. A total of 178 adult patients of both sexes with a new pulmonary infiltrate on chest radiograph, and some of the following sings and symptoms of pneumonia: chest pain, cough, positive auscultatory finding of fever (38°C) who gave their written informed consent, were randomized to receive either 1, 5 g of azithromycin as a single dose, or 500 mg once daily for 3 days, or 250 mg clarithromycin twice-daily for 10 days. Causative pathogens were identified by blood and/or sputum cultures as well as by serologic testing of antibodies directed to Mycoplasma pneumoniae, Chlamydia pneumoniae, C.psittaci, Coxiella burnetii, and urinary antigen test for legionella pneumophila. Control clinical examinations were performed 2, 3, 10-14 days and 4-5 weeks after treatment initiation. Cure was defined as disappearance of sings and symptoms of pneumonia with regression of infiltrate on chest radiograph within 10-14 days after treatment initiation and with no relapse of disease during the follow-up period. Treatment groups were comparable with respect to demographic and anamnestic data. Among 177 patients who were evaluable for clinical efficacy, most common causative pathogen were M.pneumoniae (in 98 patients) and C.pneumoniae (in 15 patients). Cure were recorded in all patients in the single dose azithromycin group, in 98.3% of patients in the 3-day azithromycin group and in 98.3% of patients in the clarithromycin group. Adverse events were in 9 patients in the single dose azithromycin group, 10 in 3-day azithromycin group, and 13 in the clarithromycin group. The results of this study showed that single 1.5 g dose of azithromycin was equally effective and well tolerated as standard 3-day azithromycin or 10-day clarithromycin course in the treatment of communitiy-acquired pneumoniae in adult patients.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Projekti:
143004
Ustanove:
Klinika za infektivne bolesti "Dr Fran Mihaljević"
Profili:
Ilija Kuzman
(autor)
Slavko Schonwald
(autor)
Višnja Škerk
(autor)
Vjekoslav Mahovlić
(autor)